This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Jaszewski B, Gao X, Reddy P, Bhardwaj T, Bjarnason G, Finelli A, Kapoor A, Abugaber A.Cost effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Canada. Journal of Clinical Oncology 25 (Suppl.): 262, No. 18, Part 1, 20 Jun 2007
Rights and permissions
About this article
Cite this article
Sorafenib a worthy opponent for advanced renal cancer. Pharmacoecon. Outcomes News 533, 3 (2007). https://doi.org/10.1007/BF03296118
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03296118